Repeated Thrombolytic Therapy in Patients with Recurrent Acute Ischemic Stroke
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Widespread use of thrombolytic treatments, along with improved chances of survival after an initial ischemic stroke, increases the possibility of repeated thrombolysis. There are few reports, however, regarding repeated thrombolysis in patients who have suffered acute ischemic stroke. We explored the number and outcome of patients with repeated thrombolytic therapy in the era of multimodal thrombolytic treatments. Methods We investigated patients with acute ischemic stroke who had received thrombolytic treatments for a period of 10 years. Number of thrombolysis was determined in each patient. Recanalization was defined as Thrombolysis in Cerebral Infarction grading ≥2a. Symptomatic hemorrhagic transformation was defined as any increase in the National Institutes of Health Stroke Scale score that could be attributed to intracerebral hemorrhage. A good outcome was defined as a modified Rankin scale score ≤2. Results Of the 437 patients who received thrombolytic treatments, only 7 underwent repeated thrombolysis (1.6%). The median age at the time of repeated thrombolytic therapy was 71 years old; 4 of the patients were female. All patients had 1 or more potential sources of cardiac embolism. Recanalization was achieved in all patients, in both the first and the second thrombolysis. No symptomatic intracranial hemorrhage occurred after repeated thrombolytic treatments. Five patients (71.4%) showed good outcomes at 3 months. Conclusions Repeated thrombolysis for recurrent acute ischemic stroke appears to be safe and feasible. Among patients who experience recurrent acute ischemic stroke, thrombolytic therapy could be considered even if the patient has had previous thrombolytic treatments.
Abstract
Background and Purpose Widespread use of thrombolytic treatments, along with improved chances of survival after an initial ischemic stroke, increases the possibility of repeated thrombolysis. There are few reports, however, regarding repeated thrombolysis in patients who have suffered acute ischemic stroke. We explored the number and outcome of patients with repeated thrombolytic therapy in the era of multimodal thrombolytic treatments. Methods We investigated patients with acute ischemic stroke who had received thrombolytic treatments for a period of 10 years. Number of thrombolysis was determined in each patient. Recanalization was defined as Thrombolysis in Cerebral Infarction grading ≥2a. Symptomatic hemorrhagic transformation was defined as any increase in the National Institutes of Health Stroke Scale score that could be attributed to intracerebral hemorrhage. A good outcome was defined as a modified Rankin scale score ≤2. Results Of the 437 patients who received thrombolytic treatments, only 7 underwent repeated thrombolysis (1.6%). The median age at the time of repeated thrombolytic therapy was 71 years old; 4 of the patients were female. All patients had 1 or more potential sources of cardiac embolism. Recanalization was achieved in all patients, in both the first and the second thrombolysis. No symptomatic intracranial hemorrhage occurred after repeated thrombolytic treatments. Five patients (71.4%) showed good outcomes at 3 months. Conclusions Repeated thrombolysis for recurrent acute ischemic stroke appears to be safe and feasible. Among patients who experience recurrent acute ischemic stroke, thrombolytic therapy could be considered even if the patient has had previous thrombolytic treatments.
참고문헌 (36)
- Nam HS, "Long-term mortality in patients with stroke of undetermined etiology", Stroke, 43, pp.2948~2956 (2012)
- Sauer R, "Repeated thrombolysis for chronologically separated ischemic strokes: a case series", Stroke, 41, pp.1829~1832 (2010)
- Banerjee P, "Repeat thrombolysis for acute myocardial infarction", Int J Cardiol, 102, pp.515~519 (2005)
- Barbash GI, "Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies", Circulation, 103, pp.954~960 (2001)
- Meneveau N, "Management of unsuccessful thrombolysis in acute massive pulmonary embolism", Chest, 129, pp.1043~1050 (2006)
- Arsava EM, "De-novo thrombolysis for recurrent stroke in a patient with prior history of thrombolysis", Blood Coagul Fibrinolysis, 21, pp.605~607 (2010)
- Topakian R, "Thrombolysis beyond the guidelines: two treatments in one subject within 90 hours based on a modified magnetic resonance imaging brain clock concept", Stroke, 36, pp.162~164 (2005)
- Brigo F, "Repeated systemic thrombolysis after early recurrent stroke: always hazardous?", Can J Neurol Sci, 39, pp.114~116 (2012)
- Chiti A, "A case of recurrent basilar artery occlusion successfully treated with repeated intravascular procedures", Neurologist, 17, pp.95~97 (2011)
- Saver JL, "Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial", Lancet, 380, pp.1241~1249 (2012)
- Yoon W, "Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute ischemic stroke after failure of intravenous thrombolysis", AJNR Am J Neuroradiol, 31, pp.161~164 (2010)
- Broderick JP, "Endovascular therapy after intravenous t-PA versus t-PA alone for stroke", N Engl J Med, 368, pp.893~903 (2013)
- Noser EA, "Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke?", Stroke, 36, pp.292~296 (2005)
- Lee BI, "Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions", Cerebrovasc Dis, 12, pp.145~151 (2001)
- Wahlgren N, "Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study", Lancet, 369, pp.275~282 (2007)
- Heo JH, "Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study", Neurology, 60, pp.1684~1687 (2003)
- Lee KY, "Rescue treatment with abciximab in acute ischemic stroke", Neurology, 56, pp.1585~1587 (2001)
- Lee KY, "Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke", AJNR Am J Neuroradiol, 25, pp.1470~1147 (2004)
- Nam HS, "Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients", J Neurol Sci, 281, pp.69~73 (2009)
- "The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group", N Engl J Med, 333, pp.1581~1587 (1995)
- Hacke W, "Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Nam HS, "Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging", Thromb Haemost, 107, pp.786~794 (2012)
- Higashida RT, "Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke", Stroke, 34, pp.109~137 (2003)
- Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
- De Keyser J, "Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations", Stroke, 38, pp.2612~2618 (2007)
- Acheampong P, "Pharmacokinetics of alteplase in the treatment of ischaemic stroke", Expert Opin Drug Metab Toxicol, 8, pp.271~281 (2012)
- Andrew Bivard, "Review of Stroke Thrombolytics", 대한뇌졸중학회지, 15(2), pp.90~98 (2013), 대한뇌졸중학회
- Cappellari M, "Intravenous thrombolysis on early recurrent cardioembolic stroke: ‘Dr Jekyll’ or ‘Mr Hyde’?", Blood Coagul Fibrinolysis, 23, pp.78~81 (2012)
- White HD, "Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction", Br Heart J, 64, pp.177~181 (1990)
- Hill MD, "Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke", CMAJ, 162, pp.1281~1284 (2000)
- Reed BR, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients", Thromb Haemost, 64, pp.276~280 (1990)
- Cugno M, "Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein", Thromb Haemost, 76, pp.234~238 (1996)
- Pechlaner C, "Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase", Blood Coagul Fibrinolysis, 12, pp.491~494 (2001)
- Awadh M, "Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation", Stroke, 41, pp.1990~1995 (2010)
- Yalcin-Cakmakli G, "Right internal carotid artery occlusion during intravenous thrombolysis for left middle cerebral artery occlusion", J Stroke Cerebrovasc Dis, 18, pp.74~77 (2009)
- Furie KL, "Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association", American Stroke Association, 2012, pp.43, 3442~3453